Edmonton, May 28-30, 2023

Due to the numerous requests from LPs. Micro and Craft growers along with some of the largest cannabis retail stores in the nation, Grow Up has decided to bring our award winning show to Alberta. We will be hosting our 7th Conference and Expo at the Edmonton Convention Centre in beautiful downtown Edmonton.

Study Finds Ethnicity, Race Linked to Mental Health Outcomes and Psychedelic Use

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

Psychedelics have become popular in the recent times, with growing evidence showing that the substances may be beneficial in the treatment of mental health disorders such as anxiety and depression. One such study found that the administration of psychedelics was linked to significant improvements in anxiety and depression symptoms as well as increased emotional well-being.

Now, a new study has discovered that ethnicity and race moderate the link between major depressive episodes and the use of psychedelic drugs. Grant M. Jones, a Harvard University clinical psychology PhD student and the author of the study, revealed that the main objective was to determine how identity may impact the link between psychedelics and mental health.

For his research, Jones obtained data gathered in the period between 2005–2019 from the National Survey on Drug Use and Health. The data included responses from 596,187 adults in the United States, including non-Hispanic whites, Hispanic individuals and non-Hispanic racial minorities.

During the survey, participants were required to report if they had used drugs such as psilocybin and MDMA. Jones analyzed the data then controlled for age, sex, engagement in risky behavior, educational attainment, marital status, household income and the use of other drugs. This led to the discovery that the use of psilocybin and MDMA was linked to reduced odds of past-year severe depression and lifetime depression among non-Hispanic whites.

Among Hispanic participants, the use of these drugs was linked to decreased odds of past year depression. Jones also observed that the use of psilocybin and MDMA were not linked to depression among Asian, Black and multiracial participants. In addition, he found that the use of the aforementioned drugs was linked to increased odds of past-year depression and lifetime depression among indigenous participants.

In his report, Jones stated that his observations were consistent with separate studies that looked into the association between psychological distress, suicidality and the use of psilocybin and MDMA. He highlighted that his discovery brought up questions about whether similar links could be observed in a treatment setting and argued that it was possible unaccounted for demographic factors contributed to the study’s findings.

With Matthew K. Nock, the researchers also indicated possible mechanisms that could underlie their findings, noting that a person’s environment and mindset could have a significant impact on the effects of these drugs. They explained that discrimination, racism and prejudice were ingrained features in the minority experience and negatively impacted their psychedelic experience greatly.

The study’s findings were reported in the “Journal of Psychopharmacology.”

As more entities such as Seelos Therapeutics Inc. (NASDAQ: SEEL) conduct their psychedelics development programs, a lot more is set to emerge about how various factors influence the psychedelic experience of users and contribute to the therapeutic effects of these substances.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.